Thiotetrabarbital is a thiobarbituric acid derivative patented by "Centre national de la recherche scientifique" as a short-acting anesthetic agent useful in veterinary medicine.

Retelleptine (SR-95325 B) is an antitumoral agent. This ellipticine derivative exhibits high toxicity against several rodent tumor models. Retelliptine is thought to intercalate with DNA and inhibit topoisomerase II during DNA replication. A phase I study reported possible drug-related toxicity sporadically such as somnolence, bronchospasm, dry mouth, and vomiting.

Salmisteine was studied as an antipyretic and mucolytic agent. Information about the current use of this compound is not available.

Etisulergine (CQ 32-084) is an ergoline derivative. Etisulergine stimulates both dopamine D1- and D2-receptors, antagonizes alpha-adrenergic and serotonin 5-HT2 receptors. Etisulergine demonstrated antiparkinsonian activity in patients.

Auriclosene (previously known as NVC-422) is a broad-spectrum, fast-acting topical anti-infective agent against microbial pathogens, including antibiotic-resistant microbes. It has been investigated in phase II clinical trials for the treatment of bacterial conjunctivitis and as a topical gel in children with impetigo. In addition, using a guinea pig model was shown, that auriclosene was effective in the treatment of dermatophytosis, including onychomycosis.

Hydroxytoluic acid is a long-acting derivative of salicylate with antilipidemic properties. It shows fibrinolytic activity in human plasma by activating the fibrinolytic system and has been shown to lower plasma free fatty acid, cholesterol levels, and to raise metabolic oxygen consumption.

Droclidinium is the muscarinic receptors antagonist. It is an anticholinergic, spasmolytic agent.

Nifuroquine is an antibacterial agent, used in the treatment of bovine mastitis.